Research Analysts Offer Predictions for OBIO Q3 Earnings

Key Points

• HC Wainwright lowered its Q3 2026 EPS estimate for Orchestra BioMed to a loss of $0.41 per share from $0.39, while maintaining a Buy rating and $10 price target.
• Orchestra BioMed’s latest results modestly exceeded expectations, with an EPS loss of $0.38 versus the $0.39 consensus estimate, although quarterly revenue of $0.09 million fell short of the $0.14 million forecast.
• Analyst sentiment remains broadly positive, with six Buy ratings, one Hold and one Sell, producing a “Moderate Buy” consensus and an average price target of $13.00.

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) - Investment analysts at HC Wainwright reduced their Q3 2026 earnings per share estimates for shares of Orchestra BioMed in a research note issued on Wednesday, August 12th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.41) for the quarter, down from their previous estimate of ($0.39). HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Orchestra BioMed's current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Orchestra BioMed's FY2026 earnings at ($1.52) EPS, Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.42) EPS, Q3 2027 earnings at ($0.40) EPS and FY2027 earnings at ($1.63) EPS.

Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.01. Orchestra BioMed had a negative return on equity of 127.86% and a negative net margin of 184.60%.The company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.14 million.

Several other research analysts also recently commented on the stock. Wall Street Zen downgraded shares of Orchestra BioMed from a "hold" rating to a "sell" rating in a report on Saturday, May 16th. Piper Sandler reaffirmed an "overweight" rating and set a $10.00 price objective (up from $9.00) on shares of Orchestra BioMed in a report on Tuesday. Weiss Ratings restated a "sell (e+)" rating on shares of Orchestra BioMed in a research report on Friday, July 17th. B. Riley Financial dropped their price objective on shares of Orchestra BioMed from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Tuesday, May 19th. Finally, Barclays lifted their price target on Orchestra BioMed from $12.00 to $13.00 and gave the stock an "overweight" rating in a research report on Wednesday, May 13th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $13.00.

Orchestra BioMed Trading Up 0.7%

NASDAQ:OBIO opened at $4.45 on Friday. The business has a fifty day moving average price of $4.01 and a 200-day moving average price of $4.11. The company has a debt-to-equity ratio of 0.35, a current ratio of 7.03 and a quick ratio of 7.01. Orchestra BioMed has a one year low of $2.20 and a one year high of $5.42. The firm has a market capitalization of $267.44 million, a price-to-earnings ratio of -5.24 and a beta of 0.50.

Institutional Trading of Orchestra BioMed

Several large investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in Orchestra BioMed in the 2nd quarter valued at $10,832,000. Vanguard Group Inc. increased its position in Orchestra BioMed by 28.0% during the third quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company's stock worth $3,675,000 after purchasing an additional 324,558 shares during the last quarter. Alyeska Investment Group L.P. purchased a new position in Orchestra BioMed during the third quarter worth about $3,386,000. Pathstone Holdings LLC purchased a new position in Orchestra BioMed during the third quarter worth about $2,495,000. Finally, Geode Capital Management LLC boosted its holdings in Orchestra BioMed by 22.4% in the 4th quarter. Geode Capital Management LLC now owns 473,363 shares of the company's stock valued at $1,965,000 after purchasing an additional 86,564 shares during the last quarter. 53.20% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Orchestra BioMed

In other news, insider Darren Sherman sold 15,000 shares of the stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $4.09, for a total transaction of $61,350.00. Following the sale, the insider directly owned 1,154,327 shares of the company's stock, valued at $4,721,197.43. This represents a 1.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.50% of the stock is owned by insiders.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc NASDAQ: OBIO is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company's research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed's pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source